Side-by-side · Research reference

ChonlutenvsMOTS-c

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-StrongHUMAN-REVIEWED16/68 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

01Mechanism of Action

Parameter

Chonluten

MOTS-c

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Feedback intact?

—

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

MOTS-c

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

4–12 weeks (experimental)

Optimal cycle length unknown.

Clinical validation

None (PubMed indexed)

—

Standard dose

—

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

Lower / starter dose

—

2.5–5 mg / week

Recommended due to limited human data.

Reconstitution

—

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Timing

—

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

Half-life

—

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

03Metabolic / Fat Loss Evidence

Parameter

Chonluten

MOTS-c

Primary fat target

—

Diet-induced / metabolic obesity; systemic fat utilization

Quantified reduction

—

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

IGF-1 impact

—

No direct IGF-1 pathway; AMPK-mediated

Effect on lean mass

—

High dose significantly ↑ lean mass in mice

Insulin sensitivity

—

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

Triglycerides

—

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

Glucose metabolism

—

Improved glucose tolerance; GLUT4 upregulationLee 2015

Effect reversibility

—

Unknown — no long-term follow-up data

Context dependency

—

No effect in normal-chow mice; requires metabolic stressReynolds 2021

Key publication

—

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

04Side Effects & Safety

Parameter

Chonluten

MOTS-c

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Injection site reaction

—

Mild irritation (reported)

Fluid retention / Edema

—

Not reported

Glucose intolerance

—

Improves glucose toleranceLee 2015

Cardiovascular

—

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

Cancer risk

—

Contradictory data — some models suggest pro-proliferative effects

CNS / Neurological

—

Insomnia, headache (anecdotal reports)

GI symptoms

—

Nausea, stomach discomfort (reported)

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid — insufficient safety data

Evidence quality

—

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

05Administration Protocol

Parameter

Chonluten

MOTS-c

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

06Stack Synergy

Chonluten

— no documented stacks

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction